trial
as of 2026-07-01AMP SCZ® Observational Study: PREDICT-DPACC
NCTId NCT05905003
at a glance
Phase — · Active Not Recruiting
Enrollment 2,617 (estimated)
Sponsored by Brigham and Women's Hospital
Primary completion 2027-04-30
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Active Not Recruiting
Enrollment
2,617 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2022-06-02
Primary completion
2027-04-30
Eligibility
ALL · 12 Years · 30 Years
Interventions & indications
Drugs
—
Sponsors
Brigham and Women's HospitalLead Sponsor
OrygenCollaborator
Yale UniversityCollaborator
National Institute of Mental Health (NIMH)Collaborator
Investigators
3
Martha E Shenton, Ph.D.Principal Investigator
Scott Woods, M.D.Principal Investigator
Barnaby Nelson, Ph.D.Principal Investigator
Sites
42 total
Irvine, United StatesLos Angeles, United StatesSan Diego, United StatesSan Francisco, United StatesHartford, United StatesNew Haven, United StatesAthens, United StatesEvanston, United StatesBoston, United StatesSt Louis, United StatesNew York, United StatesQueens, United States
Facts & assertions
4 sourced
Enrollment
2,617
Phase
NA
Primary Completion Date
2027-04-30
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
lead_sponsor
company
collaborator
company
company
indication
investigator